STALICLA: Valuation, Funding & Investors
STALICLA SA is a Swiss clinical-stage biopharmaceutical company developing precision-medicine approaches for neurodevelopmental and neuropsychiatric disorders. The company employs a multi-omics DEPI platform to identify patient subgroups and match them with targeted therapeutic candidates; its pipeline includes subgroup-matched programs such as STP1 for Autism Spectrum Disorder and STP7 for Substance Use Disorder, and it conducts clinical collaborations to advance these programs.
Leadership & Board
- Current Number of Employees
- 23
- Current LinkedIn Followers
- 5,882
Latest Estimated Valuation
- Total Amount Raised
- $3M
- Total Funding Rounds
- 1
- Latest Funding Amount
- $3M
- Latest Funding Round
- Investment
Company Momentum Positive
STALICLA LinkedIn following is increasing, signaling rising market interest, while its workforce is growing, indicating business expansion.
Employee Trend
STALICLA had 23 employees as of October 26, 2026. The number of employees increased by 0 (0.00%) week-over-week.
Social Trend
STALICLA had 5,882 followers as of October 26, 2026. The number of followers increased by 4 (0.07%) week-over-week.
Funding Round
| Funding Date | Funding Round | Amount Raised | Post-Money Valuation |
|---|---|---|---|
| Jul 30, 2025 | Investment | $2.50M | ― |
Investors
| Investor Name | Funding Round |
|---|---|
| Addex Therapeutics | Investment |
Similar Companies
A snapshot of private companies similar to STALICLA, helping you discover and navigate related company profiles.
Related News and Analysis
